JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $81
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $79 to $81.
August 21, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has reaffirmed its Overweight rating on Intra-Cellular Therapies and increased the price target from $79 to $81, indicating a positive outlook.
The increase in price target from $79 to $81 by JP Morgan suggests a positive outlook for ITCI, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100